CDK4 and breast cancer: On the other hand, recent data indicated that the CDK-RB-E2F pathway was reactivated in CDK4/6 inhibitor-resistant BC cell lines, but it was sensitive to mammalian target of rapamycin complex1/2 (mTORC1/2) inhibitors.